Frontiers in psychiatry · 2026
Peripheral complement C3 and C4 are associated with clinical features of schizophrenia.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Szwajca Marta, Śmierciak Natalia, Biesaga Beata, Donicz Paulina, Szwajca Krzysztof, Pilecki Maciej
Аннотация
AIM: Schizophrenia is a severe psychiatric disorder with heterogeneous outcomes; factors such as anxiety, childhood trauma, and duration of untreated psychosis (DUP) may influence symptom severity and disease progression. Growing evidence highlights immune dysregulation-particularly alterations in complement components C3 and C4-in the pathophysiology of schizophrenia; however, findings regarding peripheral complement levels and their clinical associations remain inconsistent.
METHOD: Thirty-nine patients with schizophrenia underwent clinical assessment using the Childhood Trauma Questionnaire (CTQ), the Positive and Negative Syndrome Scale (PANSS), the State-Trait Anxiety Inventory (STAI), and the Montreal Cognitive Assessment (MoCA). Serum concentrations of C3 and C4 were measured at admission.
RESULTS: In exploratory analyses (nominal p-values), baseline C3 correlated with DUP (r=0.407, p=0.010) and length of hospitalization (r=0.353, p=0.028). Higher C3 was associated with greater symptom severity on PANSS-P1 (r=0.325, p=0.043) and PANSS-G1 (r=0.330, p=0.040), while C4 correlated with PANSS-G1 (r=0.322, p=0.045) and multiple PANSS domains after 12 weeks. C3 was associated with anxiety at baseline and after 3 months (STAI-T1: r=0.376, p=0.018; STAI-S1: r=0.372, p=0.020; STAI-T2: r=0.376, p=0.018; STAI-S2: r=0.419, p=0.009), whereas C4 correlated with STAI-T1 (r=0.361, p=0.024), STAI-S1 (r=0.342, p=0.033), and STAI-S2 (r=0.338, p=0.038). Higher C3 and C4 levels were associated with CTQ subscales. C3 correlated negatively with cognitive performance (MoCA1: r=-0.339, p=0.034). However, none of the associations survived Benjamini-Hochberg false discovery rate (BH-FDR) correction (all q>0.05).
CONCLUSION: These exploratory, within-cohort findings suggest that peripheral complement markers relate to variation in clinical severity and illness-course indicators in schizophrenia. Replication in larger, controlled longitudinal studies is warranted.
METHOD: Thirty-nine patients with schizophrenia underwent clinical assessment using the Childhood Trauma Questionnaire (CTQ), the Positive and Negative Syndrome Scale (PANSS), the State-Trait Anxiety Inventory (STAI), and the Montreal Cognitive Assessment (MoCA). Serum concentrations of C3 and C4 were measured at admission.
RESULTS: In exploratory analyses (nominal p-values), baseline C3 correlated with DUP (r=0.407, p=0.010) and length of hospitalization (r=0.353, p=0.028). Higher C3 was associated with greater symptom severity on PANSS-P1 (r=0.325, p=0.043) and PANSS-G1 (r=0.330, p=0.040), while C4 correlated with PANSS-G1 (r=0.322, p=0.045) and multiple PANSS domains after 12 weeks. C3 was associated with anxiety at baseline and after 3 months (STAI-T1: r=0.376, p=0.018; STAI-S1: r=0.372, p=0.020; STAI-T2: r=0.376, p=0.018; STAI-S2: r=0.419, p=0.009), whereas C4 correlated with STAI-T1 (r=0.361, p=0.024), STAI-S1 (r=0.342, p=0.033), and STAI-S2 (r=0.338, p=0.038). Higher C3 and C4 levels were associated with CTQ subscales. C3 correlated negatively with cognitive performance (MoCA1: r=-0.339, p=0.034). However, none of the associations survived Benjamini-Hochberg false discovery rate (BH-FDR) correction (all q>0.05).
CONCLUSION: These exploratory, within-cohort findings suggest that peripheral complement markers relate to variation in clinical severity and illness-course indicators in schizophrenia. Replication in larger, controlled longitudinal studies is warranted.